Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323)

BACKGROUND: The EORTC 24971/TAX 323, a phase III study of 358 patients with unresectable locoregionally advanced squamous cell carcinoma of the head and neck, showed an improved progression-free and overall survival (OS) with less toxicity when docetaxel (T) was added to cisplatin and 5-fluorouracil...

Descripción completa

Detalles Bibliográficos
Autores principales: van Herpen, C M L, Mauer, M E, Mesia, R, Degardin, M, Jelic, S, Coens, C, Betka, J, Bernier, J, Remenar, E, Stewart, J S, Preiss, J H, van den Weyngaert, D, Bottomley, A, Vermorken, J B
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967049/
https://www.ncbi.nlm.nih.gov/pubmed/20842129
http://dx.doi.org/10.1038/sj.bjc.6605860

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967049/
https://www.ncbi.nlm.nih.gov/pubmed/20842129
http://dx.doi.org/10.1038/sj.bjc.6605860

Ejemplares similares